|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Statistics** | **Spartalizumab (*N* = 82)** | |
| **Cycle 1** | **Cycle 3** |
| **AUCtau (day•µg/mL)a** | *n* | 73 | 39 |
| Geo-mean | 1340 | 2260 |
| Geo-CV% | 25.8 | 30.6 |
| **Cmax (µg/mL)** | *n* | 78 | 47 |
| Geo-mean | 116 | 149 |
| Geo-CV% | 21.9 | 25.8 |
| **Tmax (hr)** | *n* | 78 | 47 |
| Median | 1.57 | 1.57 |
| Range | 0.583–3.17 | 1.00–14.9 |
| AUCtau, AUC is calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1); Cmax, maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1); PK, pharmacokinetics;  Tmax time taken to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time). *N* = number of patients with corresponding evaluable PK parameters. a AUCtau was AUC0-672 hours. | | | |

**Supplemental Table S7. Primary PK parameters for spartalizumab**